Superior results for Supernus

Supernus Pharmaceuticals Inc., of Rockville, a specialty pharmaceutical company focused on products for treatment of central nervous system diseases, reported a profit of about $3.2 million, or 8 cents per diluted share, for the quarter ended June 30, after having lost nearly $27.4 million, or 89 cents per share, in the prior-year period. The increase is primarily due to the year-over-year growth in product revenue coupled with the impact of issuing convertible debt, Supernus said. Revenue for the quarter was almost $29.7 million, compared with $281,000 in 2013.

Leave a Reply

Your email address will not be published. Required fields are marked *